SUPN (STOCKS)
Supernus Pharmaceuticals, Inc.
$43.860000
-0.550000 (-1.24%)
Prev close: $44.410000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jack A. Khattar
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,545.62M
- Employees
- 674
- P/E (TTM)
- -85.68
- P/B (TTM)
- 2.39
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
6
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$0.60 | $0.30 | +0.2965 | +97.69% |
|
Dec 2025 (Q4)
|
$0.84 | $0.35 | +0.4932 | +142.21% |
|
Sep 2025 (Q3)
|
$1.01 | $0.60 | +0.4082 | +67.83% |
|
Jun 2025 (Q2)
|
$0.90 | $0.48 | +0.4206 | +87.73% |
Financial Statements
| Revenues | $776.83M |
| Benefits Costs and Expenses | $825.98M |
| Cost Of Revenue | $82.19M |
| Costs And Expenses | $837.19M |
| Gross Profit | $694.64M |
| Nonoperating Income/Loss | $11.21M |
| Operating Expenses | $755.00M |
| Selling, General, and Administrative Expenses | $520.79M |
| Depreciation and Amortization | $2.00M |
| Research and Development | $118.75M |
| Other Operating Expenses | $113.46M |
| Operating Income/Loss | -$60.36M |
| Income/Loss From Continuing Operations After Tax | -$29.02M |
| Income/Loss From Continuing Operations Before Tax | -$49.15M |
| Income Tax Expense/Benefit | -$20.13M |
| Income Tax Expense/Benefit, Deferred | $15.11M |
| Net Income/Loss | -$29.02M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$29.02M |
| Net Income/Loss Available To Common Stockholders, Basic | -$29.02M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.51 |
| Diluted Earnings Per Share | -$0.51 |
| Basic Average Shares | 170,542,278 |
| Diluted Average Shares | 171,160,696 |
| Assets | $1.50B |
| Current Assets | $731.58M |
| Inventory | $110.77M |
| Other Current Assets | $620.81M |
| Noncurrent Assets | $769.15M |
| Fixed Assets | $10.04M |
| Intangible Assets | $549.71M |
| Other Non-current Assets | $209.39M |
| Liabilities | $423.92M |
| Current Liabilities | $373.93M |
| Accounts Payable | $10.17M |
| Wages | $24.21M |
| Other Current Liabilities | $339.55M |
| Noncurrent Liabilities | $49.99M |
| Equity | $1.08B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.08B |
| Liabilities And Equity | $1.50B |
| Net Cash Flow From Operating Activities | $83.26M |
| Net Cash Flow From Operating Activities, Continuing | $83.26M |
| Net Cash Flow From Investing Activities | -$52.43M |
| Net Cash Flow From Investing Activities, Continuing | -$52.43M |
| Net Cash Flow From Financing Activities | $39.64M |
| Net Cash Flow From Financing Activities, Continuing | $39.64M |
| Net Cash Flow | $70.47M |
| Net Cash Flow, Continuing | $70.47M |
| Comprehensive Income/Loss | -$29.07M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$29.11M |
| Other Comprehensive Income/Loss | -$51.57M |
| Other Comprehensive Income/Loss Attributable To Parent | -$96.00K |